Zepbound Outperforms CagriSema in Head-to-Head Phase III Obesity Trial A pivotal Phase III trial has delivered a setback for Novo Nordisk, after its obesity candidate CagriSema was outperformed by Eli Lillys Zepbound (tirzepatide) in a direct comparison study
Outcomes differ: Approximately 70% of patients experienced significant weight loss after 6 months of semaglutide treatment
Sharma I, Yadav KS, Mugale MN (2022) Redoxisome and diabetic retinopathy: pathophysiology and therapeutic interventions
In adipocytes lacking CI, we observed reduced expression of genes involved in the response to insulin stimulus and PI3K/protein kinase B signal transduction (Fig
The American Journal of Sports Medicine, 48 (8), 1916-1928
The same angiogenesis that helps a damaged tendon can in theory help a tumor get a blood supply, which is why oncologists pay attention to this mechanism even though no study has shown BPC-157 causes cancer